Polymorphisms in Toll-like receptor genes and risk of cancer

El-Omar, Emad; Ng, Mike T.; Hold, Georgina L.

doi:10.1038/sj.onc.1210912

Cited by 211 publications

(174 citation statements)

References 62 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…9,16 The TLR2 -196 to -174 del/ins polymorphism has further been shown to be associated with cervical cancer, 11 an increased risk of noncardiac gastric cancer 12 and the severity of intestinal metaplasia in gastroduodenal disease. Importantly, the TLR2 -196 to -174 del/ins polymorphism has been recently proposed to reflect differential…”

Section: Discussionmentioning

confidence: 99%

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C

Nischalke

Coenen

Berger

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is a major risk factor for hepatocellular carcinoma (HCC). HCV proteins core and NS3 can bind to toll-like receptor 2 (TLR2) and trigger inflammatory responses. Polymorphisms in the TLR2 gene predispose to various forms of malignancy but have not been studied in HCV-associated HCC. Here, we investigated whether single nucleotide polymorphisms (SNPs), rs4696480, rs5743708, rs5743704 and the -196 to -174 del/ins polymorphism of the TLR2 gene affect the risk for HCC in chronic hepatitis C. The study involved 189 and 192 HCV genotype 1 infected patients with and without HCC, respectively, as well as 347 healthy controls. TLR2 alleles were determined by hybridization probe assays and allele-specific short fragment polymerase chain reaction on a LightCycler system. All TLR2 polymorphisms matched the HardyWeinberg equilibrium in each study group. Although TLR2 SNPs showed no effect, the frequency of the TLR2 -196 to -174 del allele was significantly higher in patients with HCV-associated HCC (22.5%) than in HCV-infected patients without HCC (15.6%, p 5 0.016) and healthy controls (15.3%, p 5 0.003). HCV-infected carriers of a TLR2 -196 to -174 del allele had significantly higher HCV viral loads than TLR2 -196 to -174 ins/ins homozygous patients (p 5 0.031). Finally, in carriers of the TLR2 -196 to -174 del allele, stimulation of monocytes resulted in significantly lower TLR2 expression levels and interleukin-8 (IL-8) induction than in individuals with the TLR2 -196 to -174 ins/ins genotype (p < 0.05). Our data suggest the TLR2 -196 to -174 del allele to affect HCV viral loads and to increase the risk for HCC in HCV genotype1-infected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C

Nischalke

Coenen

Berger

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…In mouse model, loss of MIF delayed the onset of B-cell lymphoma (Talos et al, 2005). Also even in Helicobacter pylori induced gastric cancer, MIF-TLR4 activity promotes the production of factors necessary for cancer progression (Bifulco et al, 2008;El-Omar et al, 2008). MIF's role in many cancers and in the different stages is becoming clearer with the studies being carried out across the globe.…”

Section: Mif and Tumorsmentioning

confidence: 99%

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Babu¹,

Chetal²,

Kumar³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Macrophage migration inhibitory factor (MIF) is a pluripotent cytokine which plays roles in inflammation, immune responses and cancer development. It assists macrophages in carrying out functions like phagocytosis, adherence and motility. Of late, MIF is implicated in almost all stages of neoplasia and expression is a feature of most types of cancer. The presence of MIF in almost all tumors and all stages of cancer makes it an interesting candidate for cancer therapy. This review explores the roles of MIF in neoplasia.

show abstract

“…TLR2, one of the well characterized TLRs, initially implicated in the recognition of lipopolysaccharide (LPS), is located on chromosome 4q32 protein coding gene . Many single-nucleotide polymorphisms (SNPs) of TLR2 have been reported that they may be correlated with cancer risk and progression in some genetic studies (El-Omar et al, 2008;Kutikhin,2011). TLR2+597T>C (rs3804099), +1350C>T (rs3804100), Arg753Gln (rs5743708) are three most widely studied sites.…”

Section: Introductionmentioning

confidence: 99%

Lack of Association of Three Common Polymorphisms in Toll-like receptors (TLRs), TLR2+597T>C, +1350C>T and Arg753Gln with Cancer Risk: a Meta-analysis

Yang

Wang²,

Qiu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Polymorphisms in Toll-like receptor genes and risk of cancer

Cited by 211 publications

References 62 publications

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C

Macrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy

Lack of Association of Three Common Polymorphisms in Toll-like receptors (TLRs), TLR2+597T>C, +1350C>T and Arg753Gln with Cancer Risk: a Meta-analysis

Contact Info

Product

Resources

About